Media release of March 19, 2025 Shareholders at BB Biotech AG’s AGM vote in favor of all proposals and approve the dividend of CHF 1.80 per share All proposals of BB Biotech AG's Board of Directors were approved by BB Biotech AG's shareholders at its Annual General Meeting held today. Shareholders voted in favor of the proposal to pay out a divi [ … ]

Media release as at February 21, 2025 Annual Report 2024: BB Biotech positions for structural sector recovery amid shifting market dynamics 2024, especially the fourth quarter, signaled the early stage of a structural recovery in biotech, driven by renewed investor focus on clinical data, regulatory approvals, and commercial execution. BB Biotec [ … ]

Media release as of January 24, 2025 BB Biotech: Preliminary full-year 2024 results and dividend proposal BB Biotech AG reports the following preliminary and unaudited figures for 2024: Full-year 2024: BB Biotech shares delivered a total return of -13.5% in CHF and -14.1% in EUR (including the CHF 2.00 dividend paid in March 2024). NAV performan [ … ]

  London, UK, 22 January 2025   Edison issues report on BB Biotech (BION) Edison issues report on BB Biotech (BION). BB Biotech (BION) is the largest biotech investor among its investment company peers. The company is focused on achieving long-term capital growth by investing in high-quality biotech assets developing and marketing innovative d [ … ]